The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma
Open accessAbstract
Although aberrant DNA methylation patterning is a hallmark of cancer, the relevance of targeting DNA methyltransferases (DNMT) remains unclear for most tumors. In diffuse large B-cell lymphoma (DLBCL) we observed that chemoresistance is associated with aberrant DNA methylation programming. Prolonged exposure to low-dose DNMT inhibitors (DNMTI) reprogrammed chemoresistant cells to become doxorubicin sensitive without major toxicity in vivo. Nine genes were recurrently hypermethylated in chemoresistant DLBCL. Of these, SMAD1 was a critical contributor, and reactivation was required for chemosensitization. A phase I clinical study was conducted evaluating azacitidine priming followed by standard chemoimmunotherapy in high-risk patients newly diagnosed with DLBCL. The combination was well tolerated and yielded a high rate of complete remission. Pre- and post-azacitidine treatment biopsies confirmed SMAD1 demethylation and chemosensitization, delineating a personalized strategy for the clinical use of DNMTIs. Significance: The problem of chemoresistant DLBCL remains the most urgent challenge in the clinical management of patients with this disease. We describe a mechanism-based approach toward the rational translation of DNMTIs for the treatment of high-risk DLBCL. Cancer Discov; 3(9); 1002–19. ©2013 AACR. See related commentary by Steinhardt and Gartenhaus, p. 968 This article is highlighted in the In This Issue feature, p. 953
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53
Schmitt, C. A., McCurrach, M. E., de Stanchina, E., Wallace-Brodeur, R. R., & Lowe, S. W. (1999) · Genes & Development · doi:10.1101/gad.13.20.2670 · Cited by 458
DNA end joining becomes less efficient and more error-prone during cellular senescence
Seluanov, A., Mittelman, D., Pereira-Smith, O. M., Wilson, J. H., & Gorbunova, V. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400726101 · Cited by 278
Pharmacology of 5-Aza-2′-deoxycytidine (decitabine)
Momparler, R. L. (2005) · Seminars in Hematology · doi:10.1053/j.seminhematol.2005.05.002 · Cited by 231
Cited by
Epigenetic Determinants of Cancer
Baylin, S. B., & Jones, P. A. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019505 · Cited by 1,226
Li, S., Young, K. H., & Medeiros, L. J. (2018) · Pathology · doi:10.1016/j.pathol.2017.09.006 · Cited by 649
Friedberg, J. W., & Fisher, R. I. (2008) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2008.07.002 · Cited by 362
The timeline of epigenetic drug discovery: from reality to dreams
Ganesan, A., Arimondo, P. B., Rots, M. G., Jeronimo, C., & Berdasco, M. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0776-0 · Cited by 341
Epigenetics-targeted drugs: current paradigms and future challenges
Dai, W., Qiao, X., Fang, Y., Guo, R., Bai, P., Liu, S., Li, T., Jiang, Y., Wei, S., Na, Z., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02039-0 · Cited by 339
Metadata
- Authors
- Clozel, T., Yang, S., Elstrom, R. L., Tam, W., Martin, P., Kormaksson, M., Banerjee, S., Vasanthakumar, A., Culjkovic, B., Scott, D. W., Wyman, S., Leser, M., Shaknovich, R., Chadburn, A., Tabbo, F., Godley, L. A., Gascoyne, R. D., Borden, K. L., Inghirami, G., Leonard, J. P., Melnick, A., & Cerchietti, L.
- Venue
- Cancer Discovery
- Published
- 2013-09-01
- Volume
- 3
- Issue
- 9
- Pages
- 1002-1019
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2143505663
- Cited by
- 222
- References
- 4
- FWCI
- 9.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.